Single nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma

Kevin C. Johnson,An-Chi Tien,Jun Jiang,James McNamara,Yu-Wei Chang,Chelsea Montgomery,Anita DeSantis,Leonel Elena-Sanchez,Yoko Fujita,Seongho Kim,Avishay Spitzer,Paul Gabriel,William F. Flynn,Elise Courtois,Amy Hong,Jocelyn Harmon,Yoshie Umemura,Artak Tovmasyan,Jing Li,Shwetal Mehta,Roel G.W. Verhaak,Nader Sanai

DOI: https://doi.org/10.1101/2024.06.07.24308439

2024-06-07

Abstract:Outcomes for adult patients with a high grade glioma continue to be dismal and new treatment paradigms are urgently needed. To optimize the opportunity for discovery, we performed a phase 0/1 dose escalation clinical trial that investigated tumor pharmacokinetics, pharmacodynamics, and single nucleus transcriptomics following combined ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) treatment in recurrent high-grade glioma. Patients with a recurrent high-grade glioma (n = 24) harboring 1) CDKN2A/B deletion or CDK4/6 amplification, 2) PTEN loss or PIK3CA mutations, and 3) wild-type retinoblastoma protein (Rb) were enrolled. Patients received neoadjuvant ribociclib and everolimus treatment and no dose limiting toxicities were observed. The median unbound ribociclib concentrations in Gadolinium non enhancing tumor regions were 170 nM (range, 65 to 1770 nM) and 634 nM (range, 68 to 2345 nM) in patients receiving 5 days treatment at the daily dose of 400 and 600 mg, respectively. Unbound everolimus concentrations were below the limit of detection (< 0.1 nM) in both enhancing and non-enhancing tumor regions at all dose levels. We identified a significant decrease in MIB1 positive cells suggesting ribociclib associated cell cycle inhibition. Single nuclei RNAseq (snRNA) based comparisons of 17 IDH wild type on-trial recurrences to 31 IDH wild type standard of care treated recurrences data demonstrated a significantly lower fraction of cycling and neural progenitor-like (NPC like) malignant cell populations. We validated the CDK4/6 inhibitor directed malignant cell state shifts using three patient derived cell lines. The presented clinical trial highlights the value of integrating pharmacokinetics, pharmacodynamics, and single nucleus transcriptomics to assess treatment effects in phase 0/1 surgical tissues, including malignant cell state shifts. ClinicalTrials.gov identifier: .

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to improve the treatment effect of patients with recurrent high - grade glioma (HGG) by combining the treatment of cyclin - dependent kinase 4/6 (CDK4/6) inhibitor ribociclib and mammalian target of rapamycin (mTOR) inhibitor everolimus, and overcome the drug - resistance problem that may occur in single - drug treatment.

Specifically, the researchers designed a phase 0/1 clinical trial, aiming at:

1. **Evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs in tumor tissues**:
- Measuring the total and free concentrations of ribociclib and everolimus in enhanced and non - enhanced tumor areas, plasma and cerebrospinal fluid (CSF).
- Determining the penetration of these drugs in the central nervous system (CNS).

2. **Identifying molecular effects**:
- Understanding the impact of drugs on target pathways by evaluating the changes of proximal pharmacodynamic markers such as pRb, pS6 and p4EBP1.
- Analyzing the changes of malignant cell states by single - nucleus RNA sequencing (snRNAseq), especially the proportion changes of neural precursor - like cells (NPC - like) and proliferating cells.

3. **Determining the maximum tolerated dose (MTD)**:
- Determining the maximum tolerated dose of the combination treatment of ribociclib and everolimus to ensure the best efficacy without causing dose - limiting toxicity.

4. **Verifying the transformation of malignant cell states**:
- Conducting in vitro experiments using patient - derived cell lines to verify whether ribociclib can specifically reduce the states of proliferating cells and NPC - like cells and promote the transformation to more differentiated cell states.

By integrating PK/PD analysis and single - nucleus transcriptomics data, the researchers hope to quickly and comprehensively understand the impact of these two drugs on tumor cell biology and whether they can change the malignant cell states by pharmacological means. This research provides an important reference for future clinical trials, especially in evaluating the effects and mechanisms of new anti - cancer drugs.